{"name":"Scynexis, Inc.","slug":"scynexis-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":257000,"revenueGrowth":0,"grossMargin":1392.2,"rdSpend":22280000,"netIncome":-8609000,"cash":21259000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Echinocandin","genericName":"Echinocandin","slug":"echinocandin","indication":"Other","status":"discontinued"},{"name":"PRA","genericName":"PRA","slug":"pra","indication":"Invasive candidiasis","status":"marketed"}]}],"pipeline":[{"name":"Echinocandin","genericName":"Echinocandin","slug":"echinocandin","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PRA","genericName":"PRA","slug":"pra","phase":"marketed","mechanism":"PRA (prasifungin) is an antifungal agent that inhibits fungal cell wall synthesis by targeting glucan synthase.","indications":["Invasive candidiasis","Invasive aspergillosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPbEVSM3pJY04xM19tc0MtbEw0UnliYTJwc2xTbGJYRjNOOTkyUXpEVUtQM3RMcjNmS1lsU1dPRk5EN0pKRWtYUHNLOXpCTWJCY1A2c3VsNGs4U3l4eFYxUldfQnU0M1cxRGNZOG1JMVY1TjNPOHNCUG93dnl2ajcxampiRUJ3dVI3amdsUGFmX2JMLVJiZUdvLXpUVGZKSjBNZW5IWUw1OGUxeTJ4bUh0ZDNaSnlYZ0xlVlJsYU5mTVAzRF9VVjRHTQ?oc=5","date":"2026-03-31","type":"pipeline","source":"Contract Pharma","summary":"Poxel Sells Kidney‑Disease Drug Candidate to Scynexis for Up to $196 Million - Contract Pharma","headline":"Poxel Sells Kidney‑Disease Drug Candidate to Scynexis for Up to $196 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPVGkzQzlvbVJUa215Z3Joc3FrVWc2SnR4a3k2VnJNWDVzeERfalFKMThpODNEOERsejRMZFZzOEc3Tks1T1BlWERkaWZsdmpaOFlOeTFqRk5GQmhBb0RIZGxQWUp5blRtZXR4cG1GbWZaMjBBVk9kbU9CNUhueUNiOEZrWGNzc0k4TzBaRmZ1S2dZU2NOWS1ZampxbWlfdVNpUHdFQmE5d200WDlJUmdIbTYzM2pqbWIwTEgzOE1ScTJaZ3hB?oc=5","date":"2026-03-31","type":"pipeline","source":"BioSpace","summary":"Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - BioSpace","headline":"Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5lRlVEYmdQU3RnbGJMVXZMSXNGR1hIT2V1QkpmeFBTMnd4Uk1IZVcwOUFidnRkUTNUb1RySUZjbm9vWHZWNGNTc215Y19uS3N0V0o2SFdWNTduVFJhNjQ4VU9GcFBHZTkyYjN3LU1n?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Scynexis (SCYX) - Stock Titan","headline":"If You Invested $1,000 in Scynexis (SCYX)","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQVWQxTDdWUnBzTFRkS0t4WDhMd08yQnpMekljN3ZqTnl3QjJwRU9nd05JY0lpRzZNMlNSa3Z3OGVLeFd2OVZIOFFaSm1sWUdWYXdaVTl4QVpDMG1lTFp5ajVuclFuU3JzNjdwUlNaeFFxSm9GSTVmcTdYaWZQS251akZEeGVUNmV6QVdvWm9JSThrdm5Id1JlblRRMUxPZTdDWVVuSXJId1p1a3ZhNlpwU0xCbEtIa2FhVHY4VDN0VEIwaUhab2otOUJ6RldaajNFTHZLZEtqTVNjNTRobDVkdm1DNklLbmhYbUZ0SDIyT1FtaTFyYlgwRUtXeVR0ZjhDLUptMEZpVV9DWE4ySFhtVWlDMDA4TF9LbHpvVmhjbWw3TkVl?oc=5","date":"2026-02-09","type":"pipeline","source":"PR Newswire UK","summary":"Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period","sentiment":"neutral"},{"date":"2025-11-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQRW52MlU2VF84djcwVVM4T2E1c09TRl9PQkZZdDVreUd0ZmdaWE5jRVUwTkphaERCZERHM2w5WVpQSWhhT0VUWEM3TGhVRlV6dDJfZ1JOSmRnUlFmSm9iLW85ak9HZE5SLTVFUmhjcE5kUXhacFJYOXB3VnB0dmlfamprQWs5WGFjdHNWSXRrdGgxRjRkSWVwM3FHUjI2QkFtYWg1THNVNnBNQ0E?oc=5","date":"2025-09-02","type":"pipeline","source":"Bloomberg Law News","summary":"Scynexis Released from Investor’s Lawsuit Over Drug Recall Risk - Bloomberg Law News","headline":"Scynexis Released from Investor’s Lawsuit Over Drug Recall Risk","sentiment":"neutral"},{"date":"2025-08-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNaG5NTkRHSXo3cmhUNFZOUzI1MWkyWUE2MWphZkZTOVVTVUVGeGF5dlpDSUh1TVd4MEwwMVJEM1FUU3Jaa3J0Szg1TGt5ZnZpRlJNdTdWSnRFZDB2YlYzbk92VWRWVFdEOVBtaUhNV2JJVFA1MHpmQ2ZnSTVIV3N3M195Q2dYdmVBeEx5Um0zWjNnU1k?oc=5","date":"2025-05-28","type":"trial","source":"Fierce Pharma","summary":"Scynexis says GSK on hook for $10M payment after phase 3 Brexafemme trial starts back up - Fierce Pharma","headline":"Scynexis says GSK on hook for $10M payment after phase 3 Brexafemme trial starts back up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOZm1OeXlQMW9vQmxrVHRLUTY5QVpUQ0dxYTZlSkg3Y21jb2M1V1ZFS0pCbDR4YXZrcm9oeEo1dVRJRjhEWUdYcWloTDdNNnFZSlpXMVQ1RUF5eVM3Y2lMLWZpMDV1bi1vV0VGVlNqODFtX1h4eGl0OHREU1d2Rnk5SFpkTWZyVGdGTVJpZUdsaE5RMldxQUtOLTVfT1dNUEV4OUJ3U1dGeHpQYk8tVUJzXzIweEFyNUZGTExuQjZR?oc=5","date":"2025-05-16","type":"regulatory","source":"Fierce Pharma","summary":"After 19 months, FDA lifts clinical hold on vaginal yeast infection drug Brexafemme - Fierce Pharma","headline":"After 19 months, FDA lifts clinical hold on vaginal yeast infection drug Brexafemme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQcXpybXYwbXJPQlI4ZEV3VC1uRlZJSnZDZUx2X2FiTFhFUnVqaXkyWmpSWFplU3VKZWxJeGZvdkwtaVBTa20xNjlJY3RzbThxZWJmZkRNaXZ4WGJsaVAzUEppSEtRbmxuTWdENnlqd3hrakhuSXd2MUp5em8xT2M0dTFFaEc3UGhCOXJlOW9KWHBpVUgyTUVMLXFaLWpFOFBiS2dSYnlXUXJscEJmSHU1VFAtN3RkRmx6NGRURHVzWGkyVDJWZlkyOWU5ck9MZ1BOMy1CSHJ0LXlNNmVfVU1iT1lhRDUyV3VEVEI5aDAzUQ?oc=5","date":"2023-12-18","type":"earnings","source":"Seeking Alpha","summary":"Scynexis: Stock Has Been Punished Enough: GSK Partnership, Revenue Potential Warrant A Buy - Seeking Alpha","headline":"Scynexis: Stock Has Been Punished Enough: GSK Partnership, Revenue Potential Warrant A Buy","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"discontinued":1,"marketed":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":257000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":257000,"period":"2017-12-31"},{"value":257000,"period":"2016-12-31"},{"value":64000,"period":"2016-09-30"},{"value":64000,"period":"2016-06-30"},{"value":64000,"period":"2016-03-31"},{"value":257000,"period":"2015-12-31"}],"grossProfit":3578000,"grossProfitHistory":[],"rdSpend":22280000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-8609000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":21259000,"cashHistory":[],"totalAssets":59027000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}